Biotechnology and Pharmaceuticals

March 15, 2019

Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), bluebird bio, Inc. (NASDAQ:BLUE), ProQR Therapeutics N.V. (NASDAQ:PRQR), Intellia Therapeutics (NASDAQ:NTLA), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), InflaRx NV (NASDAQ:IFRX), ChemoCentryx, Inc. (NASDAQ:CCXI), Madrigal Pharmaceuticals (NASDAQ:MDGL), Celgene Corporation (NASDAQ:CELG), VBI Vaccines Inc. (NASDAQ:VBIV), Acer Therapeutics (NASDAQ:ACER), SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Proteon Therapeutics, Inc. (NASDAQ:PRTO), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Chiasma (NASDAQ:CHMA), Veru (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Medicenna Therapeutics Corp. (OTCMKTS:MDNAF), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Wave Life Sciences Ltd (NASDAQ:WVE), Merck & Company, Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Pfizer, Inc. (NYSE:PFE), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), MacroGenics, Inc. (NASDAQ:MGNX), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Astrazeneca PLC (NYSE:AZN), Novartis AG (NYSE:NVS), Strongbridge Biopharma plc (NASDAQ:SBBP), Moderna (NASDAQ:MRNA), Spark Therapeutics, Inc. (NASDAQ:ONCE), Mustang Bio, Inc. (NASDAQ:MBIO), CEL-SCI Corporation (NYSEAMERICAN:CVM), Eli Lilly and Company (NYSE:LLY), vTv Therapeutics Inc (NASDAQ:VTVT), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ProMIS Neurosciences (TSE:PMN), BioPorto A/S (CPH:BIOPOR), InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), True Leaf Medicine International Ltd. (OTCMKTS:TRLFF), Auris Medical Holding AG (NASDAQ:EARS)

Buy ($175)

Biotechnology and Pharmaceuticals

October 05, 2018

Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Cymabay Therapeutics Inc. (NASDAQ:CBAY), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), ChemoCentryx, Inc. (NASDAQ:CCXI), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Allergan, Inc. (NYSE:AGN), AbbVie Inc. (NYSE:ABBV), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), Madrigal Pharmaceuticals (NASDAQ:MDGL), InflaRx NV (NASDAQ:IFRX), Ra Pharmaceuticals (NASDAQ:RARX), Jounce Therapeutics (NASDAQ:JNCE), Arcus Biosciences (NYSE:RCUS), ObsEva SA (NASDAQ:OBSV), Kindred Biosciences, Inc. (NASDAQ:KIN), NuCana plc (NASDAQ:NCNA), Verastem, Inc. (NASDAQ:VSTM), Cerecor Inc. (NASDAQ:CERC), Avenue Therapeutics, Inc. (NASDAQ:ATXI), CEL-SCI Corporation (NYSEAMERICAN:CVM), ImmuCell Corporation (NASDAQ:ICCC), Moleculin Biotech, Inc. (NASDAQ:MBRX), Innovest Global, Inc. (OTCMKTS:IVST), CytoDyn Inc. (OTCMKTS:CYDY), Immutep Limited (NASDAQ:IMMP), ERYTECH Pharma (NASDAQ:ERYP), Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB), Aquestive Therapeutics (NASDAQ:AQST), NanoViricides, Inc. (NYSEAMERICAN:NNVC), Entera Bio Ltd. (NASDAQ:ENTX)

Buy ($175)

Proprietary Genome Editing Platforms

September 14, 2018

Companies covered: Oxford BioMedica plc (LON:OXB), miRagen Therapeutics, Inc. (NASDAQ:MGEN), IDEXX Laboratories, Inc. (NASDAQ:IDXX), The Medicines Company (NASDAQ:MDCO), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Cooper Companies, Inc. (The) (NYSE:COO), Johnson & Johnson (NYSE:JNJ), Marathon Petroleum Corporation (NYSE:MPC), Pioneer Natural Resources Company (NYSE:PXD), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Andeavor (NYSE:ANDV), Spark Therapeutics, Inc. (NASDAQ:ONCE), Audentes Therapeutics (NASDAQ:BOLD), Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), Zogenix, Inc. (NASDAQ:ZGNX), Novartis AG (NYSE:NVS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Selecta Biosciences Inc (NASDAQ:SELB), ViewRay Inc. (NASDAQ:VRAY), Novocure Ltd. (NASDAQ:NVCR), Nightstar Therapeutics PLC (NASDAQ:NITE), Dentsply Sirona (NASDAQ:XRAY), Gilead Sciences, Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG), Qiagen N.V. (NASDAQ:QGEN), Cancer Genetics, Inc. (NASDAQ:CGIX), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Sorrento Therapeutics, Inc. (NASDAQ:SRNE), Merck & Company, Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), Bausch Health Companies (NYSE:BHC), Abeona Therapeutics (NASDAQ:ABEO), Acer Therapeutics (NASDAQ:ACER), HTG Molecular Diagnostics (NASDAQ:HTGM), Intec Pharma (NASDAQ:NTEC), Fate Therapeutics, Inc. (NASDAQ:FATE), bluebird bio, Inc. (NASDAQ:BLUE), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Unum Therapeutics (NASDAQ:UMRX), Blueprint Medicines Corp. (NASDAQ:BPMC), AVROBIO (NASDAQ:AVRO), Voyager Therapeutics (NASDAQ:VYGR), Fortress Biotech, Inc. (NASDAQ:FBIO), Interpace Diagnostics Group, Inc. (NASDAQ:IDXG), GenSight Biologics SA (EPA:SIGHT), Mustang Bio, Inc. (NASDAQ:MBIO)

Buy ($175)

Medical Devices

July 13, 2018

Companies covered: Medtronic, Inc. (NYSE:MDT), Baxter International Inc. (NYSE:BAX), Abbott Laboratories (NYSE:ABT), Tactile Systems Technology, Inc. (NASDAQ:TCMD), DexCom, Inc. (NASDAQ:DXCM), Inogen, Inc (NASDAQ:INGN), Edwards Lifesciences Corporation (NYSE:EW), ABIOMED, Inc. (NASDAQ:ABMD), Intuitive Surgical, Inc. (NASDAQ:ISRG), Amazon.com, Inc. (NASDAQ:AMZN), VolitionRX Limited (NYSEAMERICAN:VNRX), CryoPort Inc. (NASDAQ:CYRX), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Bristol-Myers Squibb Company (NYSE:BMY), Pfizer, Inc. (NYSE:PFE), Dare Bioscience (NASDAQ:DARE), Merck & Company, Inc. (NYSE:MRK), Biomerica Inc. (NASDAQ:BMRA), Allergan, Inc. (NYSE:AGN), Hologic, Inc. (NASDAQ:HOLX), International Business Machines Corporation (NYSE:IBM), Restoration Robotics, Inc. (NASDAQ:HAIR), Cure Pharmaceutical Holding Corp. (OTCMKTS:CURR), Motus GI Holdings, Inc. (NASDAQ:MOTS), Co-Diagnostics, Inc. (NASDAQ:CODX), electroCore, Inc. (NASDAQ:ECOR), ReWalk Robotics Ltd (NASDAQ:RWLK), CryoLife, Inc. (NYSE:CRY), Cardiovascular Systems, Inc. (NASDAQ:CSII), SurModics, Inc. (NASDAQ:SRDX), Johnson & Johnson (NYSE:JNJ), Insulet Corporation (NASDAQ:PODD), BioTelemetry, Inc. (NASDAQ:BEAT), UnitedHealth Group Incorporated (NYSE:UNH), CVS Health Corporation (NYSE:CVS), Aetna Inc. (NYSE:AET), Cigna Corporation (NYSE:CI), Express Scripts Holding Company (NASDAQ:ESRX)

Buy ($175)

Proprietary Genome Editing Platforms

March 16, 2018

Companies covered: Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Novartis AG (NYSE:NVS), Gilead Sciences, Inc. (NASDAQ:GILD), bluebird bio, Inc. (NASDAQ:BLUE), Cellectis S.A. (NASDAQ:CLLS), Monsanto Company (NYSE:MON), Illumina, Inc. (NASDAQ:ILMN), Foundation Medicine, Inc. (NASDAQ:FMI), CRISPR Therapeutics AG (NASDAQ:CRSP), uniQure N.V. (NASDAQ:QURE), Spark Therapeutics, Inc. (NASDAQ:ONCE), AveXis Inc (NASDAQ:AVXS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Regenxbio Inc (NASDAQ:RGNX), Oxford BioMedica plc (LON:OXB), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), GenSight Biologics SA (EPA:SIGHT), ToolGen (KONEX:199800), Lysogene SA (EPA:LYS), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Intrexon Corporation (NYSE:XON), Pfizer, Inc. (NYSE:PFE), Celgene Corporation (NASDAQ:CELG), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Rocket Pharmaceuticals (NASDAQ:RCKT), Audentes Therapeutics (NASDAQ:BOLD), Fibrocell Science Inc (NASDAQ:FCSC)

Buy ($175)